Sino Biopharm hooks AstraZeneca, GSK for separate respiratory partnerships

PartnershipPDE3/4 inhibitorPositive

AI Analysis

Summary

Sino Biopharmaceutical announced separate drug development and sales partnerships with AstraZeneca and GSK for respiratory therapies, with the AstraZeneca deal involving a $200M licensing agreement for a PDE3/4 inhibitor.

Importance:6/10

Sentiment:

0.60

partnershiplicensingrespiratoryPDE inhibitorAstraZenecaGSK

Related Companies

$AZN $GSK

Read the original article

Published by Endpoints News on July 8, 2026 10:56 AM

Read Original